Brokerages Expect Evolus Inc (EOLS) Will Announce Earnings of -$0.51 Per Share

Wall Street analysts predict that Evolus Inc (NASDAQ:EOLS) will announce earnings of ($0.51) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Evolus’ earnings. The company is scheduled to issue its next earnings results after the market closes on Monday, November 5th.

On average, analysts expect that Evolus will report full year earnings of ($2.08) per share for the current year, with EPS estimates ranging from ($2.11) to ($2.04). For the next fiscal year, analysts expect that the company will report earnings of ($1.29) per share, with EPS estimates ranging from ($1.92) to ($0.66). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Evolus.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Thursday, August 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.05).

A number of research firms recently issued reports on EOLS. ValuEngine raised Evolus from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. Zacks Investment Research raised Evolus from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research report on Thursday, July 26th. JMP Securities reaffirmed an “outperform” rating and issued a $35.00 target price on shares of Evolus in a research report on Thursday, August 2nd. Cantor Fitzgerald set a $35.00 target price on Evolus and gave the company a “buy” rating in a research report on Thursday, August 2nd. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Monday, August 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Evolus has a consensus rating of “Buy” and an average price target of $30.40.

Shares of EOLS traded up $0.20 during midday trading on Monday, hitting $13.47. The stock had a trading volume of 214,174 shares, compared to its average volume of 343,903. Evolus has a twelve month low of $6.75 and a twelve month high of $39.50. The company has a market capitalization of $353.98 million and a price-to-earnings ratio of -49.89.

In related news, Director Kristine Romine bought 10,000 shares of the stock in a transaction that occurred on Wednesday, August 22nd. The shares were acquired at an average price of $19.83 per share, with a total value of $198,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael M. Jafar bought 12,800 shares of the stock in a transaction that occurred on Friday, September 14th. The stock was bought at an average cost of $20.83 per share, for a total transaction of $266,624.00. The disclosure for this purchase can be found here.

Several large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new position in Evolus during the second quarter worth approximately $108,000. Tower Research Capital LLC TRC increased its position in Evolus by 761.4% during the second quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock worth $183,000 after buying an additional 5,794 shares during the last quarter. Schwab Charles Investment Management Inc. acquired a new position in Evolus during the second quarter worth approximately $258,000. Alpine Woods Capital Investors LLC acquired a new position in Evolus during the second quarter worth approximately $280,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in Evolus during the second quarter worth approximately $303,000. 13.13% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Recommended Story: Return on Investment (ROI) Defined, Explained

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply